Gross Margin % is calculated as gross profit divided by its revenue. ImmuCell's Gross Profit for the
three
months ended in Dec. 2023 was $1.26 Mil. ImmuCell's Revenue for the
three
months ended in Dec. 2023 was $5.10 Mil. Therefore, ImmuCell's Gross Margin % for the quarter that ended in Dec. 2023 was 24.69%.
Warning Sign:
ImmuCell Corp gross margin has been in long-term decline. The average rate of decline per year is -11.6%.
The historical rank and industry rank for ImmuCell's Gross Margin % or its related term are showing as below:
ICCC'
s Gross Margin % Range Over the Past 10 Years
Min: 22.14 Med: 48.2 Max: 61.11
Current: 22.15
During the past 13 years, the highestGross Margin % of ImmuCell was 61.11%. The lowest was 22.14%. And the median was 48.20%.
ICCC's Gross Margin % is ranked worse than 83.67% of 735
companies
in the Biotechnology industry
Industry Median: 59.86
vs ICCC: 22.15
ImmuCell had a gross margin of 24.69% for the quarter that ended in Dec. 2023 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for ImmuCell was -11.60% per year.
ImmuCell Gross Margin % Historical Data
The historical data trend for ImmuCell's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ImmuCell's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell Gross Margin % Distribution
For the Biotechnology industry and Healthcare sector, ImmuCell's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ImmuCell's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ImmuCell (NAS:ICCC) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ImmuCell had a gross margin of 24.69% for the quarter that ended in Dec. 2023 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ImmuCell Gross Margin % Related Terms
Thank you for viewing the detailed overview of ImmuCell's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICCC has been successfully added to your 